Literature DB >> 9821958

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.

L Fajas1, J C Fruchart, J Auwerx.   

Abstract

PPARgamma is a member of the peroxisome proliferator activated receptors (PPAR) subfamily of nuclear receptors. So far two PPARgamma isoforms, PPARgamma1 and PPARgamma2, were known in mammals. We describe the structure of a novel human PPARgamma subtype, PPARgamma3. The PPARgamma3 mRNA is transcribed from a novel promoter localized 5' of exon A2. PPARgamma3 mRNA expression was restricted to adipose tissue and large intestine. Similar to human PPARgamma1 and -2, PPARy3 is activated by thiazolidinediones and prostaglandin J derivatives and binds with high affinity to a PPRE.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9821958     DOI： 10.1016/s0014-5793(98)01273-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  70 in total

1.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

2.  Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

Authors:  Lekha Saha
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 3.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

4.  Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation.

Authors:  Amin Majdalawieh; Lei Zhang; Ilia V Fuki; Daniel J Rader; Hyo-Sung Ro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

Review 5.  Emerging roles of JAK-STAT signaling pathways in adipocytes.

Authors:  Allison J Richard; Jacqueline M Stephens
Journal:  Trends Endocrinol Metab       Date:  2011-05-10       Impact factor: 12.015

6.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

7.  Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk.

Authors:  Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

Review 8.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 9.  mTOR, metabolism, and the regulation of T-cell differentiation and function.

Authors:  Adam T Waickman; Jonathan D Powell
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

10.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.